Donepezil HydrochlorideThird Party Manufacturing in India

Donepezil Hydrochloride is a potent, selective, noncompetitive, and rapidly reversible inhibitor of acetylcholinesterase (AChE), classified as a piperidine derivative. In Alzheimer's disease, there is a progressive loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus, leading to a deficiency of acetylcholine — a neurotransmitter critical for memory, learning, and cognitive function.

Donepezil binds reversibly to acetylcholinesterase, the enzyme responsible for hydrolyzing acetylcholine in the synaptic cleft. By inhibiting this enzyme, donepezil prevents the breakdown of acetylcholine, thereby increasing its concentration and duration of action at cholinergic synapses. This enhances cholinergic neurotransmission and temporarily improves or stabilizes cognitive function in patients with Alzheimer's disease. The drug shows relative specificity for acetylcholinesterase in the brain compared to peripheral tissues, which contributes to its tolerability profile.

Unlike other acetylcholinesterase inhibitors, donepezil has a long half-life of approximately 70 hours, allowing once-daily dosing. It provides symptomatic benefit across all stages of Alzheimer's disease — mild, moderate, and severe. While donepezil does not alter the underlying disease progression or prevent neurodegeneration, it remains the most widely prescribed acetylcholinesterase inhibitor worldwide, with demonstrated efficacy in improving cognition, global function, and activities of daily living.

Therapeutic Uses

Donepezil Hydrochloride is prescribed for the treatment of:

• Mild Alzheimer's Disease: Improves cognitive function and slows symptom progression in early-stage dementia when initiated promptly after diagnosis.
• Moderate Alzheimer's Disease: Maintains cognitive abilities and global function, helping patients retain independence in daily activities for longer periods.
• Severe Alzheimer's Disease: The only acetylcholinesterase inhibitor approved for severe Alzheimer's, providing continued symptomatic benefit even in advanced stages.
• Off-Label Uses: Includes dementia with Lewy bodies, Parkinson's disease dementia, vascular dementia, and cognitive impairment in multiple sclerosis.

Why Manufacturers Choose Donepezil Hydrochloride

Donepezil is one of the most widely prescribed anti-dementia drugs globally, with billions of patient-days of clinical experience. The molecule is off-patent in most markets, creating a substantial generic opportunity for Indian manufacturers. The API is readily available from established domestic producers with WHO-GMP and USFDA compliant facilities.

Donepezil tablets are manufactured using standard pharmaceutical processes, and the two primary dosage strengths (5mg and 10mg) cover the entire titration schedule for Alzheimer's treatment. The 23mg extended-release formulation offers a differentiated product for patients requiring higher-dose maintenance therapy. With aging populations across developed and developing markets, demand for affordable donepezil continues to grow. This makes Donepezil Hydrochloride a strategic molecule for third party manufacturing in India, serving both domestic PCD franchise networks and export markets across the US, Europe, and Asia.